We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials.
We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). We deploy our biotech healthcare platforms in these areas:
ㆍ Cancer treatment;
ㆍ Therapeutic antibodies;
ㆍ Engineered protein and enzyme drugs;
ㆍ Cellular therapies;
ㆍ Engineered viruses and bacteria;
ㆍ DNA/RNA-modifying technologies.
